Open an account

Zevra Therapeutics

ZVRA · NASDAQ

$10.47+$0.31 (+3.05%)TodayMarket closed ·
Prev close $10.16

About ZVRA

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The company is headquartered in Celebration, Florida and currently employs 61 full-time employees. The company went IPO on 2015-04-16. The company has a diverse portfolio of products and product candidates, which includes pre-clinical, clinical, and commercial stage assets. Its active commercial products and development assets include MIPLYFFA, OLPRUVA, Celiprolol, KP1077IH, KP1077N and AZSTARYS. MIPLYFFA (arimoclomol) is its approved therapy for the treatment of Niemann-Pick disease type C (NPC). OLPRUVA (sodium phenylbutyrate) is its treatment for the treatment of certain urea cycle disorders (UCDs). Celiprolol is its investigational clinical candidate for the treatment of Vascular Ehlers-Danlos Syndrome (VEDS). KP1077 is its product candidate intended for the treatment of rare sleep disorders. KP1077N is a clinical development candidate for narcolepsy. AZSTARYS is for the treatment of attention deficit and hyperactivity disorder.

Employees
61
Headquarters
Celebration, Florida
Listed
Apr 16, 2015
Sector
Health Care
Industry
Pharmaceuticals
Website
zevra.com

ZVRA key statistics

Market cap
569.87M
Price-earnings ratio
11.04
Dividend yield
—
Average volume
880.80K
Volume
431.68K
Open price
$10.31
High today
$10.56
Low today
$10.22
52 Week high
$15.04
52 Week low
$8.01

Zevra Therapeutics (ZVRA) at a glance

Zevra Therapeutics (ZVRA) last traded at $10.47, with a market cap of 569.87M and a price-to-earnings ratio of 11.04.

Today the stock has traded between $10.22 and $10.56. The current price is 2.5% above the day's low and 0.9% below its high.

Volume so far is 431.68K shares, below the average of 880.80K shares a day.

Over the past year Zevra Therapeutics has ranged from $8.01 to $15.04, and now sits 35% of the way up that range.

Zevra Therapeutics met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported $0.14 per share against an estimate of $0.1095.

The average analyst price target is $25.75, 146.0% above the current price, from 8 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 8 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 10 analystsAvg $25.75
Low
$20.20
Now
$10.47
High
$36.75

ZVRA earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 119.7% on average.

  1. Q3 FY24: reported -$0.69 per share against an estimate of -$0.4297
  2. Q4 FY24: reported -$0.69 per share against an estimate of -$0.4123
  3. Q1 FY25: reported -$0.06 per share against an estimate of -$0.1904
  4. Q2 FY25: reported $1.21 per share against an estimate of $1.53
  5. Q3 FY25: reported -$0.01 per share against an estimate of -$0.0357
  6. Q4 FY25: reported $0.21 per share against an estimate of $0.051
  7. Q1 FY26: reported $0.18 per share against an estimate of $0.0824
  8. Q2 FY26: reported $0.14 per share against an estimate of $0.1095

ZVRA news

  • Press releaseGlobe Newswire

    Zevra Therapeutics Announces Details for Q3 2026 Financial Results Call

  • Avi Kapoor

    Argenx, Caribou Biosciences And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session

  • Press releasePRNewswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA

  • Press releaseGlobe Newswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA

  • Press releaseGlobe Newswire

    Zevra Therapeutics (ZVRA) Securities Investigation Notice - Levi & Korsinsky

  • Press releasePRNewswire

    Zevra Therapeutics (ZVRA) Securities Investigation Notice - Levi & Korsinsky

  • Press releasePRNewswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA

  • Press releaseBusiness Wire

    ZVRA Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Zevra Therapeutics (ZVRA)

Similar companies

Companies in the same industry as Zevra Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.